Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The brokerage currently has a $2.25 price target on the biotechnology company’s stock. Zacks Investment Research’s price objective suggests a potential upside of 7.66% from the company’s current price.

According to Zacks, “Conatus’ third-quarter results were encouraging with the company reporting a narrower-than-expected loss. The company’s progress with its lead candidate, emricasan, has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis under the ENCORE program. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Given that there are currently no approved therapies for NASH and the significant market opportunity, the company’s efforts to develop emricasan are promising. Moreover, the company’s plans to evaluate partnership opportunities for emricasan outside North America could be rewarding, if successful. However, emricasan is still several years away from entering the market, if at all. Any development/regulatory setback could hamper the company’s prospects and impact the stock adversely.”

Several other research firms also recently weighed in on CNAT. Brean Capital set a $7.00 price target on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 5th. FBR & Co reissued an “outperform” rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research note on Tuesday, August 30th. JMP Securities reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Wednesday, November 9th. Finally, Stifel Nicolaus reduced their target price on shares of Conatus Pharmaceuticals from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, November 9th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $8.54.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 2.09 on Friday. The company has a 50 day moving average price of $1.89 and a 200 day moving average price of $2.06. The company’s market capitalization is $46.13 million. Conatus Pharmaceuticals has a 12-month low of $1.40 and a 12-month high of $4.05.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. During the same quarter in the previous year, the company earned ($0.31) earnings per share. Equities analysts anticipate that Conatus Pharmaceuticals will post ($1.28) EPS for the current year.

Several large investors have recently made changes to their positions in the stock. KCG Holdings Inc. bought a new stake in shares of Conatus Pharmaceuticals during the third quarter worth $135,000. D. E. Shaw & Co. Inc. boosted its stake in shares of Conatus Pharmaceuticals by 94.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 87,788 shares of the biotechnology company’s stock worth $175,000 after buying an additional 42,649 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,668 shares in the last quarter. Courage Capital Management LLC bought a new stake in shares of Conatus Pharmaceuticals during the third quarter worth $200,000. Finally, Vanguard Group Inc. boosted its stake in shares of Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares in the last quarter. Institutional investors and hedge funds own 22.89% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

5 Day Chart for NASDAQ:CNAT

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.